Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy
The DOI matches its Crossref record; 170 of the 170 references it cites were found in a registry or an index.
Abstract
Epidermal growth factor receptor (EGFR) is of great significance in mediating cell signaling transduction and tumor behaviors. Currently, third-generation inhibitors of EGFR, especially osimertinib, are at the clinical frontier for the treatment of EGFR-mutant non-small-cell lung cancer (NSCLC). Regrettably, the rapidly developing drug resistance caused by EGFR mutations and the compensatory mechanism have largely limited their clinical efficacy. Given the synergistic effect between EGFR and other compensatory targets during tumorigenesis and tumor development, EGFR dual-target inhibitors are promising for their reduced risk of drug resistance, higher efficacy, lower dosage, and fewer adverse events than those of single-target inhibitors. Hence, we present the synergistic mechanism underlying the role of EGFR dual-target inhibitors against drug resistance, their structure-activity relationships, and their therapeutic potential. Most importantly, we emphasize the optimal target combinations and design strategies for EGFR dual-target inhibitors and provide some perspectives on new challenges and future directions in this field.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These inhibitors act on one or more targets with additive or synergistic effects, aiming to increase efficacy, prolong therapeutic effects, minimize side effects, and lower drug doses.68,69,525”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [69]
Citations
Cites
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454
The causes and consequences of genetic heterogeneity in cancer evolution
Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013) · Nature · doi:10.1038/nature12625 · Cited by 2,262
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
Ray Chaudhuri, A., & Nussenzweig, A. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.53 · Cited by 1,786
Acetylation and deacetylation of non-histone proteins
Glozak, M. A., Sengupta, N., Zhang, X., & Seto, E. (2005) · Gene · doi:10.1016/j.gene.2005.09.010 · Cited by 1,584
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Leonetti, A., Sharma, S., Minari, R., Perego, P., Giovannetti, E., & Tiseo, M. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0573-8 · Cited by 1,409
Pirker, R., Pereira, J. R., Szczesna, A., von Pawel, J., Krzakowski, M., Ramlau, R., Vynnychenko, I., Park, K., Yu, C.-T., Ganul, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60569-9 · Cited by 1,351
Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains
Ogiso, H., Ishitani, R., Nureki, O., Fukai, S., Yamanaka, M., Kim, J.-H., Saito, K., Sakamoto, A., Inoue, M., Shirouzu, M., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00963-7 · Cited by 1,227
Yun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192
Polypharmacology: Challenges and Opportunities in Drug Discovery: Miniperspective
Anighoro, A., Bajorath, J., & Rastelli, G. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5006463 · Cited by 1,131
Corcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022
Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985
Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer
Camidge, D. R., Kim, H. R., Ahn, M.-J., Yang, J. C.-H., Han, J.-Y., Lee, J.-S., Hochmair, M. J., Li, J. Y.-C., Chang, G.-C., Lee, K. H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810171 · Cited by 980
Miller, V. A., Hirsh, V., Cadranel, J., Chen, Y.-M., Park, K., Kim, S.-W., Zhou, C., Su, W.-C., Wang, M., Sun, Y., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70087-6 · Cited by 961
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Jia, Y., Yun, C.-H., Park, E., Ercan, D., Manuia, M., Juarez, J., Xu, C., Rhee, K., Chen, T., Zhang, H., et al. (2016) · Nature · doi:10.1038/nature17960 · Cited by 886
Garrett, T. P. J., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovrecz, G. O., Zhu, H.-J., Walker, F., Frenkel, M. J., Hoyne, P. A., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00940-6 · Cited by 783
The Raf/MEK/ERK pathway: new concepts of activation
Peyssonnaux, C., & Eychène, A. (2001) · Biology of the Cell · doi:10.1016/s0248-4900(01)01125-x · Cited by 735
Wong, D. W., Leung, E. L., So, K. K., Tam, I. Y., Sihoe, A. D., Cheng, L., Ho, K., Au, J. S., Chung, L., Pik Wong, M., et al. (2009) · Cancer · doi:10.1002/cncr.24181 · Cited by 719
Takezawa, K., Pirazzoli, V., Arcila, M. E., Nebhan, C. A., Song, X., de Stanchina, E., Ohashi, K., Janjigian, Y. Y., Spitzler, P. J., Melnick, M. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0108 · Cited by 710
Recent developments in biological activities of chalcones: A mini review
Singh, P., Anand, A., & Kumar, V. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.08.033 · Cited by 710
Yang, Z., Yang, N., Ou, Q., Xiang, Y., Jiang, T., Wu, X., Bao, H., Tong, X., Wang, X., Shao, Y. W., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2310 · Cited by 542
Self-citationPolypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
Proschak, E., Stark, H., & Merk, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00760 · Cited by 498
Hosomi, Y., Morita, S., Sugawara, S., Kato, T., Fukuhara, T., Gemma, A., Takahashi, K., Fujita, Y., Harada, T., Minato, K., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01488 · Cited by 481
Ohashi, K., Sequist, L. V., Arcila, M. E., Moran, T., Chmielecki, J., Lin, Y.-L., Pan, Y., Wang, L., de Stanchina, E., Shien, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203530109 · Cited by 441
NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells
Bentires-Alj, M., Barbu, V., Fillet, M., Chariot, A., Relic, B., Jacobs, N., Gielen, J., Merville, M.-P., & Bours, V. (2003) · Oncogene · doi:10.1038/sj.onc.1206056 · Cited by 430
Douillard, J.-Y., Ostoros, G., Cobo, M., Ciuleanu, T., McCormack, R., Webster, A., & Milenkova, T. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.721 · Cited by 412
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
Bivona, T. G., Hieronymus, H., Parker, J., Chang, K., Taron, M., Rosell, R., Moonsamy, P., Dahlman, K., Miller, V. A., Costa, C., et al. (2011) · Nature · doi:10.1038/nature09870 · Cited by 396
Herbst, R. S., Ansari, R., Bustin, F., Flynn, P., Hart, L., Otterson, G. A., Vlahovic, G., Soh, C.-H., O'Connor, P., & Hainsworth, J. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60545-x · Cited by 392
Talevi, A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00205 · Cited by 381
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
Ercan, D., Choi, H. G., Yun, C.-H., Capelletti, M., Xie, T., Eck, M. J., Gray, N. S., & Jänne, P. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2789 · Cited by 368
Ramalingam, S. S., Cheng, Y., Zhou, C., Ohe, Y., Imamura, F., Cho, B. C., Lin, M.-C., Majem, M., Shah, R., Rukazenkov, Y., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.063 · Cited by 366
Janjigian, Y. Y., Smit, E. F., Groen, H. J. M., Horn, L., Gettinger, S., Camidge, D. R., Riely, G. J., Wang, B., Fu, Y., Chand, V. K., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0326 · Cited by 362
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Taniguchi, H., Yamada, T., Wang, R., Tanimura, K., Adachi, Y., Nishiyama, A., Tanimoto, A., Takeuchi, S., Araujo, L. H., Boroni, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08074-0 · Cited by 356
Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
Scott, C. L., Swisher, E. M., & Kaufmann, S. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.8848 · Cited by 355
Biswas, D. K., Cruz, A. P., Gansberger, E., & Pardee, A. B. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.15.8542 · Cited by 351
Naumov, G. N., Nilsson, M. B., Cascone, T., Briggs, A., Straume, O., Akslen, L. A., Lifshits, E., Byers, L. A., Xu, L., Wu, H.-K., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2904 · Cited by 349
Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
Gainor, J. F., & Shaw, A. T. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2029 · Cited by 346
How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets
Doak, B. C., Zheng, J., Dobritzsch, D., & Kihlberg, J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01286 · Cited by 335
Katakami, N., Atagi, S., Goto, K., Hida, T., Horai, T., Inoue, A., Ichinose, Y., Koboyashi, K., Takeda, K., Kiura, K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.0981 · Cited by 326
Histone deacetylation in epigenetics: An attractive target for anticancer therapy
Mai, A., Massa, S., Rotili, D., Cerbara, I., Valente, S., Pezzi, R., Simeoni, S., & Ragno, R. (2005) · Medicinal Research Reviews · doi:10.1002/med.20024 · Cited by 319
Third generation EGFR TKIs: current data and future directions
Tan, C.-S., Kumarakulasinghe, N. B., Huang, Y.-Q., Ang, Y. L. E., Choo, J. R.-E., Goh, B.-C., & Soo, R. A. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0778-0 · Cited by 311
Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer
Kumar, A., Petri, E. T., Halmos, B., & Boggon, T. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1178 · Cited by 308
Recent advances (2015–2016) in anticancer hybrids
Kerru, N., Singh, P., Koorbanally, N., Raj, R., & Kumar, V. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.033 · Cited by 295
Ward, R. A., Anderton, M. J., Ashton, S., Bethel, P. A., Box, M., Butterworth, S., Colclough, N., Chorley, C. G., Chuaqui, C., Cross, D. A. E., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400822z · Cited by 279
Cai, X., Zhai, H.-X., Wang, J., Forrester, J., Qu, H., Yin, L., Lai, C.-J., Bao, R., & Qian, C. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901453q · Cited by 264
Nagano, T., Tachihara, M., & Nishimura, Y. (2018) · Cells · doi:10.3390/cells7110212 · Cited by 251
Qin, S., Li, J., Wang, L., Xu, J., Cheng, Y., Bai, Y., Li, W., Xu, N., Lin, L.-Z., Wu, Q., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.3183 · Cited by 237
Self-citationIshikawa, T., Seto, M., Banno, H., Kawakita, Y., Oorui, M., Taniguchi, T., Ohta, Y., Tamura, T., Nakayama, A., Miki, H., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2008634 · Cited by 227
Johnson, B. E., Kabbinavar, F., Fehrenbacher, L., Hainsworth, J., Kasubhai, S., Kressel, B., Lin, C.-Y., Marsland, T., Patel, T., Polikoff, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.3983 · Cited by 209
Al-Obaid, A. M., Abdel-Hamide, S. G., El-Kashef, H. A., Abdel-Aziz, A. A.-M., El-Azab, A. S., Al-Khamees, H. A., & El-Subbagh, H. I. (2009) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2008.09.015 · Cited by 197
CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation
Kashima, K., Kawauchi, H., Tanimura, H., Tachibana, Y., Chiba, T., Torizawa, T., & Sakamoto, H. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0229 · Cited by 186
El-Sherief, H. A. M., Youssif, B. G. M., Abbas Bukhari, S. N., Abdelazeem, A. H., Abdel-Aziz, M., & Abdel-Rahman, H. M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.07.024 · Cited by 182
Computational Multitarget Drug Design
Zhang, W., Pei, J., & Lai, L. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00491 · Cited by 180
BRAF as therapeutic target in melanoma
Wellbrock, C., & Hurlstone, A. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.03.019 · Cited by 178
El-Sherief, H. A. M., Youssif, B. G. M., Bukhari, S. N. A., Abdel-Aziz, M., & Abdel-Rahman, H. M. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2017.12.013 · Cited by 178
Shi, P., Oh, Y.-T., Zhang, G., Yao, W., Yue, P., Li, Y., Kanteti, R., Riehm, J., Salgia, R., Owonikoko, T. K., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.07.021 · Cited by 177
Nilsson, M. B., Sun, H., Robichaux, J., Pfeifer, M., McDermott, U., Travers, J., Diao, L., Xi, Y., Tong, P., Shen, L., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz4589 · Cited by 177
Gao, Y.-S., Hubbert, C. C., & Yao, T.-P. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.042754 · Cited by 167
Yacoub, A., McKinstry, R. P., Hinman, D., Chung, T. D., Dent, P., & Hagan, M. P. (2003) · Radiation Research · doi:10.1667/0033-7587(2003)159[0439:egfair]2.0.co;2 · Cited by 165
BRAF as a potential therapeutic target in melanoma and other malignancies
Tuveson, D. A., Weber, B. L., & Herlyn, M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00189-2 · Cited by 157
Highly Potent Triazole-Based Tubulin Polymerization Inhibitors
Zhang, Q., Peng, Y., Wang, X. I., Keenan, S. M., Arora, S., & Welsh, W. J. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061142s · Cited by 157
Self-citationACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers
Mahajan, K. N., & Mahajan, N. P. (2014) · Oncogene · doi:10.1038/onc.2014.350 · Cited by 154
Camidge, D. R., Kim, D.-W., Tiseo, M., Langer, C. J., Ahn, M.-J., Shaw, A. T., Huber, R. M., Hochmair, M. J., Lee, D. H., Bazhenova, L. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.5841 · Cited by 141
Zhang, T., Qu, R., Chan, S., Lai, M., Tong, L., Feng, F., Chen, H., Song, T., Song, P., Bai, G., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01202-9 · Cited by 141
Self-citationPaz-Ares, L., Mezger, J., Ciuleanu, T. E., Fischer, J. R., von Pawel, J., Provencio, M., Kazarnowicz, A., Losonczy, G., de Castro, G., Szczesna, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70046-x · Cited by 133
Sun, L., & Carpenter, G. F. (1998) · Oncogene · doi:10.1038/sj.onc.1201731 · Cited by 129
Lin, R., Connolly, P. J., Huang, S., Wetter, S. K., Lü, Y., Murray, W. V., Emanuel, S. L., Gruninger, R. H., Fuentes‐Pesquera, A. R., Rugg, C. A., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050267e · Cited by 127
New techniques and strategies in drug discovery
Du, J., Guo, J., Kang, D., Li, Z., Wang, G., Wu, J., Zhang, Z., Fang, H., Hou, X., Huang, Z., et al. (2020) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.03.028 · Cited by 116
Self-citationWang, R., Yamada, T., Kita, K., Taniguchi, H., Arai, S., Fukuda, K., Terashima, M., Ishimura, A., Nishiyama, A., Tanimoto, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18442-4 · Cited by 115
Mahboobi, S., Sellmer, A., Winkler, M., Eichhorn, E., Pongratz, H., Ciossek, T., Baer, T., Maier, T. M., & Beckers, T. L. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100665z · Cited by 105
Mirzaei, H., & Emami, S. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.067 · Cited by 105
Hu, J., & Colburn, N. H. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-04-0070 · Cited by 98
EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR
Wu, S., Kuo, Y.-W., Chang, Y., Shih, J., Chen, Y., Tsai, M., Yu, C., Yang, C.-H., & Yang, P. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182370e30 · Cited by 95
Discovery of the Pyrrolo[2,1-f][1,2,4]triazine Nucleus as a New Kinase Inhibitor Template
Hunt, J. T., Mitt, T., Borzilleri, R. M., Gullo-Brown, J. L., Fargnoli, J., Fink, B. E., Han, W.-C., Mortillo, S., Vite, G. D., Wautlet, B. S., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049892u · Cited by 94
Lin, L., Xie, H., Li, H., Tong, L., Tang, C., Ke, C., Liu, Q., Lin, L., Geng, M., Jiang, H., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701501x · Cited by 92
LaBonte, M. J., Wilson, P. M., Fazzone, W., Russell, J., Louie, S. G., El-Khoueiry, A., Lenz, H.-J., & Ladner, R. D. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2430 · Cited by 90
Zhang, H., Gong, F.-H., Ye, J.-Q., Zhang, C., Yue, X.-H., Li, C.-G., Xu, Y., & Sun, L. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.039 · Cited by 90
Xu, G., Abad, M. C., Connolly, P. J., Neeper, M. P., Struble, G. T., Springer, B. A., Emanuel, S. L., Pandey, N. B., Gruninger, R. H., Adams, M., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.020 · Cited by 89
Masuda, C., Yanagisawa, M., Yorozu, K., Kurasawa, M., Furugaki, K., Ishikura, N., Iwai, T., Sugimoto, M., & Yamamoto, K. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4036 · Cited by 89
Chen, M. C., Chen, C. H., Wang, J.-C., Tsai, A.-C., Liou, J.-P., Pan, S.-L., & Teng, C.-M. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.330 · Cited by 86
Design and synthesis of novel pyrimido[4,5-b]azepine derivatives as HER2/EGFR dual inhibitors
Kawakita, Y., Seto, M., Ohashi, T., Tamura, T., Yusa, T., Miki, H., Iwata, H., Kamiguchi, H., Tanaka, T., Sogabe, S., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.02.014 · Cited by 86
Dual-target kinase drug design: Current strategies and future directions in cancer therapy
Sun, D., Zhao, Y., Zhang, S., Zhang, L., Liu, B., & Ouyang, L. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.112025 · Cited by 84
Self-citationThienopyrimidine-based dual EGFR/ErbB-2 inhibitors
Rheault, T., Caferro, T. R., Dickerson, S. H., Donaldson, K. H., Gaul, M. D., Goetz, A. S., Mullin, R. J., McDonald, O. B., Petrov, K. G., Rusnak, D. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.12.011 · Cited by 81
Quantification of Pathway Cross-talk Reveals Novel Synergistic Drug Combinations for Breast Cancer
Jaeger, S., Igea, A., Arroyo, R., Alcalde, V., Canovas, B., Orozco, M., Nebreda, A. R., & Aloy, P. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-0097 · Cited by 79
Romagnoli, R., Baraldi, P. G., Carriòn, M. D., Lopez-Cara, L. C., Cruz‐López, O., Tolomeo, M., Grimaudo, S., Cristina, A. D., Pipitone, R. M., Balzarini, J. M., et al. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.08.027 · Cited by 76
Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors
Ducray, R., Ballard, P. G., Barlaam, B. C., Hickinson, M. D., Kettle, J. G., Ogilvie, D., & Trigwell, C. B. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.12.035 · Cited by 76
Romaniello, D., Mazzeo, L., Mancini, M., Marrocco, I., Noronha, A., Kreitman, M., Srivastava, S., Ghosh, S., Lindzen, M., Salame, T., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0450 · Cited by 73
Zhang, H., Gong, F.-H., Li, C.-G., Zhang, C., Wang, Y., Xu, Y., & Sun, L. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.12.032 · Cited by 73
Self-citationDomarkas, J., Dudouit, F., Williams, C., Qiu, Q., Banerjee, R., Brahimi, F., & Jean‐Claude, B. J. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0600390 · Cited by 70
Romaniello, D., Marrocco, I., Nataraj, N. B., Ferrer, I., Garcia, D. D., Vaknin, I., Oren, R., Lindzen, M., Ghosh, S., Kreitman, M., et al. (2020) · Cancers · doi:10.3390/cancers12092394 · Cited by 67
Chen, Y., Wu, J., Wang, A., Qi, Z., Jiang, T., Cheng, C., Zou, F., Hu, C., Wang, W., Wu, H., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.035 · Cited by 67
Jain, A., Penuel, E., Mink, S., Schmidt, J., Hodge, A., Favero, K., Tindell, C., & Agus, D. B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3326 · Cited by 66
EGFR and Her-2 regulate the constitutive activation of NF-kappaB in PC-3 prostate cancer cells
Le Page, C., Koumakpayi, I. H., Lessard, L., Mes-Masson, A.-M., & Saad, F. (2005) · The Prostate · doi:10.1002/pros.20234 · Cited by 65
Manabe, T., Yasuda, H., Terai, H., Kagiwada, H., Hamamoto, J., Ebisudani, T., Kobayashi, K., Masuzawa, K., Ikemura, S., Kawada, I., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0956 · Cited by 64
Gray, J. E., Haura, E. B., Chiappori, A., Tanvetyanon, T., Williams, C. C., Pinder-Schenck, M. C., Kish, J. A., Kreahling, J. M., Lush, R. M., Neuger, A. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2235 · Cited by 63
Abstract 1320: Preclinical evaluation of TQB3804, a potent EGFR C797S inhibitor
Liu, X., Zhang, X., Yang, L., Tian, X., Dong, T., Ding, C. Z., Hu, L., Wu, L., Zhao, L., Mao, J. J. J., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-1320 · Cited by 63
Romagnoli, R., Baraldi, P. G., Salvador, M. K., Prencipe, F., Bertolasi, V., Cancellieri, M., Brancale, A., Hamel, E., Castagliuolo, I., Consolaro, F., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5008193 · Cited by 61
Locatelli, S. L., Cleris, L., Stirparo, G. G., Tartari, S., Saba, E., Pierdominici, M., Malorni, W., Carbone, A., Anichini, A., & Carlo‐Stella, C. (2014) · Leukemia · doi:10.1038/leu.2014.81 · Cited by 59
Hayakawa, D., Takahashi, F., Mitsuishi, Y., Tajima, K., Hidayat, M., Winardi, W., Ihara, H., Kanamori, K., Matsumoto, N., Asao, T., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13255 · Cited by 57
Romagnoli, R., Prencipe, F., Oliva, P., Baraldi, S., Baraldi, P. G., Schiaffino‐Ortega, S., Chayah, M., Salvador, M. K., Lopez-Cara, L. C., Brancale, A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01391 · Cited by 57
Ding, C., Chen, S., Zhang, C., Hu, G., Zhang, W., Li, L., Chen, Y., Tan, C., & Jiang, Y. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.10.006 · Cited by 55
Yu, W., Lü, W., Chen, G., Cheng, F., Su, H., Chen, Y., Liu, M., & Pang, X. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13961 · Cited by 54
Xu, G., Searle, L. L., Hughes, T. V., Beck, A. K., Connolly, P. J., Abad, M. C., Neeper, M. P., Struble, G. T., Springer, B. A., Emanuel, S. L., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.05.024 · Cited by 54
Miyanaga, A., Shimizu, K., Noro, R., Seike, M., Kitamura, K., Kosaihira, S., Minegishi, Y., Shukuya, T., Yoshimura, A., Kawamoto, M., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-262 · Cited by 54
Nie, K., Zhang, Z., Zhang, C., Geng, C., Zhang, L., Xu, X., Liu, S., Wang, S., Zhuang, X., Lan, K., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.04.012 · Cited by 53
Self-citationDiscovery of a potent dual ALK and EGFR T790M inhibitor
Jang, J., Son, J. B., To, C., Bahcall, M., Kim, S. Y., Kang, S. Y., Mushajiang, M., Lee, Y., Janne, P. A., Choi, H. G., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.079 · Cited by 53
Gangjee, A., Pavana, R. K., Ihnat, M. A., Thorpe, J. E., Disch, B. C., Bastian, A., Bailey‐Downs, L. C., Hamel, E., & Bai, R. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4004793 · Cited by 52
Mancini, M., Gal, H., Gaborit, N., Mazzeo, L., Romaniello, D., Salame, T. M., Lindzen, M., Mahlknecht, G., Enuka, Y., Burton, D. G., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708076 · Cited by 51
Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer
Gerber, D. E., Boothman, D. A., Fattah, F. J., Dong, Y., Zhu, H., Skelton, R. A., Priddy, L. L., Vo, P., Dowell, J. E., Sarode, V. R., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.10.008 · Cited by 51
Brahimi, F., Matheson, S. L., Dudouit, F., McNamee, J. P., Tari, A. M., & Jean‐Claude, B. J. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.039099 · Cited by 50
Guo, C., & Stark, G. R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105369108 · Cited by 50
Zhang, X., Raghavan, S., Ihnat, M. A., Thorpe, J. E., Disch, B. C., Bastian, A., Bailey‐Downs, L. C., Dybdal‐Hargreaves, N. F., Rohena, C. C., Hamel, E., et al. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.04.049 · Cited by 50
Discovery of Benzo[g]quinazolin benzenesulfonamide derivatives as dual EGFR/HER2 inhibitors
Alsaid, M. S., Al-Mishari, A. A., Soliman, A. M., Ragab, F. A.-F., & Ghorab, M. M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.061 · Cited by 50
To, K. K. W., Wu, W. K. K., & Loong, H. H.-F. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.01.036 · Cited by 49
1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC
Dokla, E. M. E., Fang, C., Abouzid, K. A. M., & Chen, C. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111607 · Cited by 49
Kawakita, Y., Banno, H., Ohashi, T., Tamura, T., Yusa, T., Nakayama, A., Miki, H., Iwata, H., Kamiguchi, H., Tanaka, T., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300185p · Cited by 48
Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors
Dong, H., Yin, H. R., Zhao, C., Cao, J., Xu, W., & Zhang, Y. (2019) · Molecules · doi:10.3390/molecules24132407 · Cited by 48
Yamada, T., Horinaka, M., SHINNOH, M., Yoshioka, T., Miki, T., & Sakai, T. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2042 · Cited by 48
Mphahlele, M. J., Maluleka, M. M., Parbhoo, N., & Malindisa, S. T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092552 · Cited by 46
Discovery of Dual FGFR4 and EGFR Inhibitors by Machine Learning and Biological Evaluation
Chen, X., Xie, W., Yang, Y., Hua, Y., Xing, G., Liang, L., Deng, C., Wang, Y., Fan, Y., Liu, H., et al. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00652 · Cited by 46
Self-citationZhang, X., Raghavan, S., Ihnat, M. A., Hamel, E., Zammiello, C. L., Bastian, A., Mooberry, S. L., & Gangjee, A. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.03.061 · Cited by 44
Aouad, M. R., Al-Mohammadi, H. M., Al-blewi, F. F., Ihmaid, S. K., Elbadawy, H. M., Althagfan, S. S., & Rezki, N. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103446 · Cited by 44
Banerjee, R., Rachid, Z., McNamee, J. P., & Jean‐Claude, B. J. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030423m · Cited by 43
Hossam, M., Lasheen, D. S., Ismail, N. S. M., Esmat, A., Mansour, A. M., Singab, A. N. B., & Abouzid, K. A. M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.12.022 · Cited by 43
Zuo, M., Zheng, Y., Lu, S., Li, Y., & Zhang, S. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.05.034 · Cited by 42
Poly ADP-ribose polymerase-1: Beyond transcription and towards differentiation
Jubin, T., Kadam, A. A., Gani, A. R., Singh, M., Dwivedi, M., & Begum, R. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.07.027 · Cited by 42
Cheng, H., Chang, Y., Zhang, L., Luo, J., Tu, Z., Lu, X., Zhang, Q., Lu, J., Ren, X., & Ding, K. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500007h · Cited by 41
Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation
Frazier, N. M., Brand, T. M., Gordan, J. D., Grandis, J. R., & Jura, N. (2018) · Oncogene · doi:10.1038/s41388-018-0537-0 · Cited by 37
The Design and Synthesis of a New Class of RTK/HDAC Dual-Targeted Inhibitors
Zhang, X., Su, M., Chen, Y., Li, J. X., & Lu, W. P. (2013) · Molecules · doi:10.3390/molecules18066491 · Cited by 37
Sadek, M. M., Serya, R. A. T., Kafafy, A. N., Ahmed, M., Wang, F., & Abouzid, K. A. M. (2013) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2013.765417 · Cited by 37
Watanabe, S., Yoshioka, H., Sakai, H., Hotta, K., Takenoyama, M., Yamada, K., Sugawara, S., Takiguchi, Y., Hosomi, Y., Tomii, K., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.01.005 · Cited by 37
Heigener, D. F., Wu, Y.-L. L. C., van Zandwijk, N., Mali, P., Horwood, K. R., & Reck, M. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.02.017 · Cited by 35
Ciuleanu, T., Ahmed, S. I., Kim, J.-H., Mezger, J. M., Park, K., Thomas, M., Chen, J., Poondru, S., VanTornout, J. M., Whitcomb, D., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.226 · Cited by 34
Self-citationHamed, M. M., Darwish, S. S., Herrmann, J. E., Abadi, A., & Engel, M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01774 · Cited by 33
Identification of DW532 as a novel anti-tumor agent targeting both kinases and tubulin
Peng, T., Wu, J., Tong, L., Li, M., Chen, F., Leng, Y.-X., Qu, R., Han, K., Su, Y., Chen, Y., et al. (2014) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.33 · Cited by 30
Mastalerz, H. A., Chang, M., Chen, P., Fink, B. E., Gavai, A. V., Han, W.-C., Johnson, W. L., Langley, D. R., Lee, F. Y., Leavitt, K. J., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.06.019 · Cited by 30
Ihmaid, S. K., Ahmed, H., & Zayed, M. F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020408 · Cited by 30
Qiu, Q., Dudouit, F., Matheson, S. L., Brahimi, F., Banerjee, R., McNamee, J. P., & Jean‐Claude, B. J. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-002-0524-5 · Cited by 29
CHEN, H.-J., JIANG, Y.-L., LIN, C.-M., TSAI, S.-C., PENG, S.-F., FUSHIYA, S., HOUR, M.-J., & YANG, J.-S. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1941 · Cited by 29
Rao, S., Larroque‐Lombard, A., Peyrard, L., Thauvin, C., Rachid, Z., Williams, C., & Jean‐Claude, B. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117215 · Cited by 29
Ding, C., Li, D., Wang, Y., Han, S.-S., Gao, C., Tan, C., & Jiang, Y. (2017) · Chinese Chemical Letters · doi:10.1016/j.cclet.2017.01.003 · Cited by 29
Self-citationSchmitt, J., Huang, S., Goodfellow, E., Williams, C., & Jean‐Claude, B. J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02008 · Cited by 29
Matheson, S. L., Brahimi, F., & Jean‐Claude, B. J. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2003.10.035 · Cited by 28
Hughes, T. V., Xu, G., Wetter, S. K., Connolly, P. J., Emanuel, S. L., Karnachi, P., Pollack, S. R., Pandey, N. B., Adams, M., Moreno-Mazza, S., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.057 · Cited by 28
Park, S. G., Kim, D., Kim, M. K., Lee, J., Rho, J. K., Jeong, S., Choi, E., Kim, C., & Hwang, J. S. (2018) · Oncology Reports · doi:10.3892/or.2018.6814 · Cited by 28
Xie, Z., Wu, K., Wang, Y., Pan, Y., Chen, B., Cheng, D., Pan, S., Guo, T., Du, X., Fang, L., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111943 · Cited by 28
Self-citationFink, B. E., Norris, D. J., Mastalerz, H. A., Chen, P., Goyal, B., Zhao, Y., Kim, S., Vite, G. D., Lee, F. Y., Zhang, H., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.11.100 · Cited by 27
Wang, G. T., Mantei, R. A., Hubbard, R. D., Wilsbacher, J. L., Zhang, Q., Tucker, L. A., Hu, X., Kovar, P. J., Johnson, E. F., Osterling, D. J., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.08.052 · Cited by 26
Self-citationAlbuschat, R., Löwe, W., Weber, M., Luger, P., & Jendrossek, V. (2004) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2004.03.010 · Cited by 26
Zhao, L., Fan, T., Shi, Z., Ding, C., Zhang, C., Yuan, Z., Sun, Q., Tan, C., Chu, B., & Jiang, Y. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113173 · Cited by 26
Bianchi, L., Bruzzese, F., Leone, A., Gagliardi, A., Puglia, M., Gennaro, E. D., Rocco, M., Gimigliano, A., Pucci, B., Armini, A., et al. (2011) · PROTEOMICS · doi:10.1002/pmic.201100092 · Cited by 24
Katsoulas, A., Rachid, Z., McNamee, J. P., Williams, C., & Jean‐Claude, B. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0179 · Cited by 24
Li, D., Qin, Y., Sun, J., Li, J., Fang, F., Du, Q., Qian, Y., Gong, H., & Zhu, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069427 · Cited by 24
Pavana, R. K., Choudhary, S., Bastian, A., Ihnat, M. A., Bai, R., Hamel, E., & Gangjee, A. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.11.026 · Cited by 24
Ciuleanu, T., Socinski, M. A., Obasaju, C. K., Luft, A. V., Szczęsna, A., Szafrański, W., Ramlau, R., Bálint, B., Molinier, O., Depenbrock, H., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.10.004 · Cited by 24
Qiu, Q., Domarkas, J., Banerjee, R., Merayo, N., Brahimi, F., McNamee, J. P., Gibbs, B. F., & Jean‐Claude, B. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0812 · Cited by 23
Pilotto, S., Bria, E., Peretti, U., Massari, F., Garassino, M. C., Pelosi, G., & Tortora, G. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182a00e37 · Cited by 17
Wu, X., Sooman, L., Lennartsson, J., Bergström, S. N., Bergqvist, M., Gullbo, J., & Ekman, S. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1710 · Cited by 17
Serial Crystallography for Structure-Based Drug Discovery
Zhu, L., Chen, X., Abola, E. E., Jing, L., & Liu, W. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.08.009 · Cited by 17
Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors
Szokol, B., Gyulavári, P., Ibolya, K., Baska, F., Szántai-Kis, C., Greff, Z., Őrfi, Z., Peták, I., Pénzes, K., Torka, R., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4003309 · Cited by 15
Li, C., Liu, W., Ning, J.-F., Meng, W.-Q., Hu, J., Zhao, Y., & Liu, C. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s85357 · Cited by 13
Generation and Assessment of Fusions Between HDACi and TKi
Mahboobi, S., Pilsl, B., & Sellmer, A. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6527-4_31 · Cited by 6
Research works printed but not linked: 4
- Swarbrick M. E., 2012, Kinase Drug Discovery, 79
- Viloria-Petit A., 2001, Cancer Res., 61, 5090
- Marais R., 1996, Cancer Surv., 27, 101
- Matheson S. L., 2001, J. Pharmacology Experimental Therapeutics, 296, 832
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“588 Iododi fl unisal ( 67 , IDIF), luteolin ( 68 ), and three marketed drugs sulindac ( 69 ), olsalazine ( 70 ), and fl ufenamic ( 71 ) are small-molecule chaperones for the TTR/A β interaction.”
BackgroundSelf-citationRecent development of multi-target VEGFR-2 inhibitors for the cancer therapy
Liu, X., Zhao, H.-C., Hou, S.-J., Zhang, H., Cheng, L., Yuan, S., Zhang, L., Song, J., Zhang, S., & Chen, S. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106425 · Cited by 142
Bispecific antibodies in cancer therapy: Target selection and regulatory requirements
Sun, Y., Yu, X., Wang, X., Yuan, K., Wang, G., Hu, L., Zhang, G., Pei, W., Wang, L., Sun, C., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.023 · Cited by 125
Self-citationAhmad, S., & Raza, K. (2023) · Molecular Diversity · doi:10.1007/s11030-023-10648-0 · Cited by 93
“Among the challenges medicinal chemists addressed was identifying polymorphism-related kinase inhibitors, one of the critical targets for EGFR tyrosine kinase inhibitors [15].”
Hu, M., Li, Y., Li, J., Zhou, H., Liu, C., Liu, Z., Gong, Y., Ying, B., & Xie, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114775 · Cited by 41
Metadata
- Authors
- Tan, L., Zhang, J., Wang, Y., Wang, X., Wang, Y., Zhang, Z., Shuai, W., Wang, G., Chen, J., Wang, C., Ouyang, L., & Li, W.
- Affiliations
- Sichuan University (CN)
- Department of Respiratory and Critical Care Medicine, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, 610041 Sichuan, China
- Corresponding author
- Wang, Chengdi
- Ouyang, Liang
- Li, Weimin
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2022-03-21
- Volume
- 65
- Issue
- 7
- Pages
- 5149-5183
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W4221034213
- Cited by
- 88
- References
- 170
- Citations by year
- 2026: 16 · 2025: 21 · 2024: 25 · 2023: 20 · 2022: 6
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Science and Technology of the People's Republic of China (2018ZX09201018-021)
- National Natural Science Foundation of China (81874290, 81903502, 81922064, 82073318)
- National Clinical Research Center for Geriatrics, Sichuan University (Z20201004)
- Sichuan Science and Technology Program (2019YFS0003)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- epidermal growth factor receptor, dual inhibitors, EGFR-mutant non-small cell lung cancer, osimertinib, drug resistance, compensatory signaling, structure-activity relationship
- MeSH terms
- Aniline Compounds, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.